CKMO-3415 is under clinical development by CK Regeon and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CKMO-3415’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CKMO-3415 is under development for the treatment of obesity. It is administered through oral route. The drug candidate acts by targeting CXXC-type zinc finger protein 5 (CXXC5). It is a new chemical entity (NCE).
CK Regeon overview
CK Biotech Inc., is a biotechnology company that discover and develop First-In-?Class drugs with clear MOA. The company is headquartered Republic of Korea (South Korea).
For a complete picture of CKMO-3415’s drug-specific PTSR and LoA scores, buy the report here.